Improved survival after one course of perioperative chemotherapy in early breast cancer patients: Long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854
Improved survival after one course of perioperative chemotherapy in early breast cancer patients: Long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854
复制标题
DOI：
10.1016/s0959-8049(01)00294-5
复制
发表时间：
2001-11-01
影响因子：
8.4
通讯作者：
Duchateau, L
中科院分区：
文献类型：
--
作者：
van der Hage, JA;van de Velde, CJH;Duchateau, L
本研究的目的是探讨在早期乳腺癌患者中，围手术期一个疗程的多化疗在生存、无进展生存期（PFS）和局部控制方面是否比单纯手术有更好的效果。从1986年到1991年，2795例I/II期乳腺癌患者被随机分为两组，一组在术后36小时内接受含蒽环类药物化疗方案的围手术期疗程，另一组单独接受手术治疗。随访患者的总生存期、PFS和局部复发情况。分析时的中位随访期为1.1年。围手术期化疗组PFS和局部控制率均显著优于对照组（P=0.025和P= 0.004）。淋巴结阴性患者似乎从围手术期FAC中获益最多。围手术期化疗加局部治疗的患者总生存率明显优于单纯局部治疗的患者（P=0.004）。接受额外全身治疗的患者似乎没有从一个疗程的围手术期化疗中获益（P = 0.65）。围手术期一个疗程的多化疗确实改善了早期乳腺癌的PFS和局部控制。在11年的随访后，这种效果仍然存在。(C) 2001年Elsevier Science Ltd.出版版权所有。
The aim of this study was to examine whether one course of perioperative polychemotherapy yields better results in terms of survival, progression-free survival (PFS) and locoregional control than surgery alone in early stage breast cancer. From 1986 to 1991, 2795 patients with stage I/II breast cancer were randomised to receive either one perioperative course of in anthracycline-containing chemotherapeutic regimen within 36 h after surgery or surgery alone. Patients were followed-up for overall survival, PFS and locoregional recurrence. The median follow-up period at time of the analysis was I I years. PFS and locoregional control were significantly better (P=0.025 and P= 0.004, respectively) in the perioperative chemotherapy arm. Node-negative patients seemed to benefit most from the perioperative FAC. Patients who received perioperative chemotherapy and locoregional therapy alone had significantly better overall survival rates than patients who received locoregional therapy alone (P=0.004). Patients who received additional systemic therapy did not seem to benefit from one course of perioperative chemotherapy (P = 0.65). One course of perioperative polychemotherapy does improve PFS and locoregional control in early stage breast cancers. This effect is still present after 11 years of follow-up. (C) 2001 Published by Elsevier Science Ltd. All rights reserved.